A 6-week randomized, double-blind study on 48 runners showed measurable gains in oxygen utilization, ventilatory threshold, and aerobic capacity at two specific daily doses.

Here Is What The Data Actually Shows

A peer-reviewed study published in the Journal of the International Society of Sports Nutrition has found that daily supplementation with nicotinamide mononucleotide, commonly referred to as NMN, produced statistically significant improvements in aerobic efficiency in active amateur runners.

The findings were published earlier this year and are freely accessible in the U.S. National Library of Medicine's research archive. The full citation is available at pmc.ncbi.nlm.nih.gov/articles/PMC8265078.

The study is drawing attention in sports medicine and longevity research circles because it is one of the first randomized, double-blind, placebo-controlled human trials to test NMN supplementation specifically on aerobic performance parameters in physically active adults. Most prior NMN research has been conducted in animal models or in sedentary older populations. This trial used people who were already training.

Here is what the researchers tested, what they measured, and what the data showed.

The Study Design

The trial enrolled 48 healthy amateur runners, ranging from young adults to middle age. Participants were divided into four groups. Three groups received daily NMN supplementation at 300 mg, 600 mg, or 1,200 mg respectively. The fourth group received a placebo. Critically, all four groups followed an identical structured training protocol for the full six weeks: 5 to 6 running sessions per week, each lasting 40 to 60 minutes. The only variable between groups was the NMN dose.

Neither the participants nor the researchers administering the supplements knew who was receiving which dose during the trial. That is the double-blind design, and it is the reason this study carries more evidential weight than observational reports or open-label trials.

Participants were assessed at baseline and again at week 6 on a battery of aerobic performance biomarkers.

The Key Findings

The results divided cleanly along dose lines.

The 600 mg and 1,200 mg groups showed measurable improvements across multiple aerobic parameters. The 300 mg group and the placebo group did not show the same gains despite identical training loads.

Here is what changed in the active dose cohorts.

Oxygen utilization improved. Skeletal muscle in the NMN groups extracted and converted oxygen to usable energy more efficiently during active exercise. This is the core metabolic process your VO2 metrics capture: not how much oxygen you inhale, but how effectively your muscle cells do something useful with it.

VO2 max percentages increased. Subjects in the 600 mg and 1,200 mg cohorts were able to sustain higher workloads before reaching their aerobic ceiling.

Ventilatory thresholds shifted upward. This is the point during exercise where breathing becomes labored and lactic acid begins accumulating in the working muscles. In the active NMN cohorts, that threshold moved to a higher exercise intensity. In practical terms: runners could push harder before hitting the wall.

What did not change is equally important to report honestly. The trial found no significant difference in absolute peak power output between NMN groups and placebo. The NMN cohorts did not produce higher maximum force. The gains were specifically in aerobic efficiency at moderate to high training intensities, not in raw ceiling performance.

Why This Matters: The NAD+ Decline Mechanism

To understand why NMN produced these effects, you need to understand what it does at the cellular level.

NAD+ (nicotinamide adenine dinucleotide) is a coenzyme that sits at the center of mitochondrial energy production. The mitochondria in your skeletal muscle cells use NAD+ as a critical cofactor in the electron transport chain, the process by which your cells convert oxygen into ATP. ATP is the energy currency every muscle contraction runs on.

The problem is that NAD+ levels decline with age. Research estimates that by the mid-40s, circulating NAD+ has dropped by roughly half compared to young adult levels. This decline does not cause a single dramatic event. It degrades mitochondrial function gradually. It shows up as reduced aerobic efficiency, slower recovery, and an earlier onset of fatigue during sustained exercise.

NMN is a direct biochemical precursor to NAD+. When you consume NMN, your cells convert it into NAD+ through a known enzymatic pathway. The hypothesis this study tested is whether supplementing with NMN could restore enough NAD+ availability to improve measurable aerobic function in active adults. The 600 mg and 1,200 mg results suggest the answer is yes, at least in the context of a structured 6-week training program.

The mechanism is not a mystery. It is substrate restoration.

The Dose Threshold

The 300 mg dose produced no significant aerobic benefit in this trial. That is a finding worth paying attention to.

The data shows a clear threshold effect beginning at 600 mg. Both the 600 mg and 1,200 mg groups outperformed the placebo. The 300 mg group did not. This means that under-dosing NMN, even while training consistently, likely produces no measurable outcome. The dose you take is not a minor detail.

What Researchers Said

The study authors noted that NMN supplementation appeared to enhance the capacity of skeletal muscle to utilize oxygen more efficiently, specifically during sustained aerobic work. The data pointed to improved mitochondrial function as the primary driver.

Dr. Pedram, founding physician at Omre, commented on the findings:

"While the study hasn't found an increase in peak fitness, NMN appears to enhance aerobic efficiency during exercise, a valuable edge for anyone committed to training and healthy aging."

That framing is accurate to the data. This is an efficiency story, not a peak performance story. For the person who already trains and wants their effort to convert more effectively into aerobic output, those are the same thing.

What This Means For Anyone Who Trains

The practical takeaway from this trial is specific. If your aerobic output has been declining despite consistent training, and you have ruled out obvious behavioral causes, the issue may not be your program. It may be the NAD+ substrate your mitochondria require to extract energy from oxygen efficiently. A training program cannot fix a substrate shortage. Only restoring the substrate can do that.

The clinical data points to a clear dose threshold. Below 600 mg of NMN daily, no significant aerobic benefit appeared in this trial. The dose is not a footnote. It is the variable that separated the groups that responded from the groups that did not.

What To Look For In An NMN Supplement

Not all NMN products are equal. Independent testing of commercially available NMN supplements has found wide variation between what is printed on the label and what is actually in the capsule. In some cases, tested products have come in at a fraction of their stated dose. Given that this trial showed zero measurable benefit at 300 mg and significant gains starting at 600 mg, a product that claims 600 mg but delivers less is functionally a placebo.

Three things matter when evaluating an NMN supplement for this purpose. The daily dose must reach 600 mg. The purity must be independently verified, not just claimed. And the manufacturing must meet pharmaceutical-grade GMP standards so the product that leaves the facility matches what was tested.

About Omre NMN + Resveratrol

Omre NMN + Resveratrol was formulated specifically around the clinical NMN research on aerobic function and healthy aging. Each serving delivers 600 mg of NMN, the threshold dose from this trial, paired with trans-resveratrol, a polyphenol that activates the sirtuin longevity pathway that NAD+ supports, and BioPerine, a standardized black pepper extract that enhances absorption of both active compounds.

The formula contains nothing else. No fillers, no unnecessary additives, no proprietary blends that obscure the actual doses.

On purity: Omre's NMN is independently third-party tested and verified at over 90 percent purity. That figure is not a marketing claim. It is a lab result from an external testing facility. The product is manufactured in a GMP-certified facility in the United States.

For anyone who has been burned by supplements that did not deliver what the label said, the third-party verification is the relevant data point. The dose printed on the bottle is the dose that has been independently confirmed in the capsule.

From People Who Actually Train

The customers below were not recruited to write reviews. These are verified purchasers who came to Omre as active adults and reported back on what they experienced.

None of these were trained runners who became sedentary and noticed a placebo lift. These are people who were already training at volume. The common thread in their reports is better oxygen efficiency, faster recovery, and sustained output at intensities that previously caused early fatigue. Those are exactly the parameters the trial measured.

If you train consistently and want to know whether your aerobic ceiling is a training problem or a substrate problem, the 6-week window in this trial is a reasonable test period.

Omre NMN + Resveratrol is available at the clinically tested 600 mg daily dose. Subscriptions include free shipping and are cancel-anytime with no commitment.

The full published trial is available at pmc.ncbi.nlm.nih.gov/articles/PMC8265078.